Journal Information
Vol. 30. Issue 3.
Pages 141-144 (March 1994)
Share
Share
Download PDF
More article options
Vol. 30. Issue 3.
Pages 141-144 (March 1994)
Full text access
Parámetros predictivos en la respuesta al tratamiento con almitrina
Predictive variables in response to treatment with almitrine
Visits
4321
J.M. González Ruiz*,1
* Servicios de Neumología. Hospital La Paz. Madrid
J. Villamor, J.M. Pino, J. Muñoz, S.D. Lobato, C. Prados
Servicios de Neumología. Hospital Clínico de Salamanca. Madrid
This item has received
Article information

El bismesilato de almitrina (BA) mejora la hipoxemia en un número indeterminado de enfermos con insuficiencia respiratoria. Nuestro objetivo en este trabajo ha sido tratar de identificar los pacientes que podían beneficiarse de este tratamiento. Se realizó un estudio a doble ciego, aleatorio con 21 enfermos, diagnosticados de bronquitis crónica obstructiva que recibieron oxigenoterapia domiciliaria, con BA (50-100 mg/día) frente a placebo, durante 3 meses (T0 a T3). La Pa02 ascendió desde 51 ± 5,3 a 58,5 ± 10 mmHg (6,8 ± 0,7 a 7,8 ± 1,3 Kpa) en los 12 pacientes con BA (p < 0,05). Los restantes parámetros gasométricos y de la exploración funcional respiratoria no se modificaron. Los 7 pacientes del grupo BA definidos como respondedores, es decir, cuya PaO2 ascendió más de 5 mmHg (0,66 Kpa) presentaban en T0 valores inferiores respecto a los 7 no respondedores del mismo grupo en: presión de oclusión con CO2, flujo inspiratorio medio, ventilación minuto tanto aire como con CO2. Estos parámetros podrían servir de predicción para la posible respuesta gasométrica al BA.

Almitrine bimesylate (AB) improves hypoxemia in an undetermined number of patients with respiratory failure. Our objective was to try to identify the patients likely to benefit from this treatment. We undertook a double blind study of AB (50-100 mg/day) vs placebo in 21 randomly chosen patients diagnosed as having chronic obstructive bronchitis who were receiving oxygen therapy in the home. The study lasted 3 months (T0 to T3). PaO2 rose from 51 ± 5.3 to 58.5 ± 10 mmHg (6.8 ± 0.7 to 7.8 ±1.3 Kpa) in the 12 patients taking AB (p < 0.05). The remaining gasometric variables and results of functional respiratory exploration were unchanged. The 7 patients receiving AB who were defined as responding -whose PaO2 rose more than 5 mmHg (0.66 Kpa)presented T0 values lower than those of the 7 non-responding patients in the same group, with respect to CO2 occlusion pressure, mean inspiratory flow and minute ventilation for both air and CO2. These variables can serve as predictors for gasometric response to AB.

Full text is only aviable in PDF
Bibliografía
[1.]
J. Metrot, J. Grand.
Essai chez l’homme d’un nouvel analeptique respiratoire 2620 SE. Note préliminaire.
Ann Anesthesiol Fr, 13 (1972), pp. 23-31
[2.]
M. Laubie, F. Diot.
Etude pharmacologique de l’action stimulante respiratoire du S-2620. Role des chemorecepteurs carotidiens et aortiques.
J Pharmacol, 3 (1972), pp. 363-374
[3.]
W. De Backer, R. Heryman, M. Willemen, P. Wermeire.
Factors determining the response to peripheral chemoreceptor stimulation by almitrine.
Eur Resp, 1 (1988), pp. 20
[4.]
A.J. Suggett, A. Proctor, H. Smyllie, M.D. Peake, R.M. Cayton, P. Howard.
Predictions of which hypoxaemic patients will respond to almitrine.
Am Rev Respir Dis, 133 (1986), pp. A339
[5.]
N.S. Cherniak.
Worshop on assessment of respiratory control in humans. Methods of measurement of ventilatory responses to hypoxia and hypercapnia.
Am Rev Respir Dis, 115 (1977), pp. 177-181
[6.]
T. Evans, J. Tweney, J. Waterhouse, J. Nichol, A. Suggett, P. Howard.
Almitrine bismesylate and oxygen therapy in hypoxic cor pulmonale.
Thorax, 45 (1990), pp. 16-21
[7.]
C. Voisin, P. Howard, J.C. Ansquer.
Almitrine bismesylate: A long-term placebo-controlled double-blind study in COAD. Vectarion International Multicentrique Study Group.
Bull Eur Physiopathol Respir, 23 (1987), pp. 169-182
[8.]
S. Watanabe, R.E. Kanner, A.G. Cutillo, R.L. Menlove, R.T. Bachand, M.B. Szalkowski, et al.
Long-term effect of almitrine bismesylate in patients with hypoxemic chronic obstructive pulmonary disease.
Am Rev Respir Dis, 140 (1989), pp. 1.269-1.273
[9.]
C. Prefaut, D. Bourgouin Karaouni, M. Ramonatxo, F.B. Michel, J. Macabies.
A one year double blind follow-up of blood gas tension and haemodynamics in almitrine bismesylate therapy.
Eur Respir J, 1 (1988), pp. 41-50
[10.]
J.M. Polu, P.H. Dagrenat, P. Sadoul.
Traitement de l’insuffisance respiratoire chronique des bronchiteux chroniques par le bismésilate d’almitrine per os. Etude contrôlée en double insu.
Bull Eur Physiopathol Respir, 18 (1982), pp. 359-371
[11.]
F. Arnaud, A. Bertrand, J. Charpin, J. Chretien, G. Decroix, J.C. Kald, et al.
Long term almitrine bismesylate treatment in patients with chronic bronchitis and emphysema. A multicentre double blind placebo controlled study.
Eur J Respir Dis, 64 (1983), pp. 323-330
[12.]
Y. Castaing, G. Manier, N. Varene, H. Guenard.
Almitrine orale et distribution des rapport VA/Q dans les bronchopneumopathies chroniques obstructives.
Bull Eur Physiopathol Respir, 17 (1981), pp. 917-932
[13.]
C. Melot, R. Naeije, T. Rothschild, P. Mertens, P. Mols, R. Hallmans.
Improvement in ventilation-perfusion matching by almitrine in COPD.
Chest, 83 (1983), pp. 528-533
[14.]
A.C. Powles, D.V. Tuxen, C.B. Mahood, S.O. Pugsley, E.J. Campbell.
The effect of intravenously administered almitrine, a peripheral chemoreceptor agonist, on patients with chronic air-flow obstruction.
Am Rev Respir Dis, 127 (1983), pp. 284-289
[15.]
P.P. Nunn, M.J. Myer, Y.T. Wang, J.P. Lavender, J.M. Hughes.
Effects of almitrine on the regional distribution of ventilation and perfusion in chronic bronchitis.
Bull Eur Physiopathol Respir, 20 (1984), pp. 37-42
[16.]
J. Tweney.
Almitrine bismesylate: current status.
Bull Eur Physiopathol Respir, 23 (1987), pp. 153-163
[17.]
N.H. Edelman.
Fármacos y mediadores en el control de la respiración.
Tratado de Neumología, pp. 148-157
Copyright © 1994. Sociedad Española de Neumología y Cirugía Torácica
Archivos de Bronconeumología
Article options
Tools

Are you a health professional able to prescribe or dispense drugs?